{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:12:25Z","timestamp":1790881945870,"version":"4.1.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We compared combination treatment with teriparatide plus raloxifene with teriparatide alone in women with postmenopausal osteoporosis in a 6-month double-blind, placebo-controlled trial that measured biochemical markers of bone turnover and BMD. Markers of bone formation and spine BMD increased similarly with teriparatide alone and combination therapy. However, combination therapy induced a significantly smaller increase in bone resorption versus teriparatide alone and significantly increased total hip BMD versus baseline.<\/jats:p>\n               <jats:p>Introduction: The effects of combining two approved treatments for osteoporosis with different modes of action were examined by comparing teriparatide [rhPTH(1\u201334)] monotherapy with combination teriparatide and raloxifene therapy.<\/jats:p>\n               <jats:p>Materials and Methods: A 6-month randomized, double-blind trial comparing teriparatide plus raloxifene (n = 69) versus teriparatide plus placebo (n = 68) was conducted in postmenopausal women with osteoporosis.<\/jats:p>\n               <jats:p>Results: Bone formation (N-terminal propeptide of type 1 collagen [PINP]) increased similarly in both treatment groups. However, the increase in bone resorption (serum C-terminal telopeptide of type I collagen [CTx]) in the combination group was significantly smaller than in the teriparatide-alone group (p = 0.015). Lumbar spine BMD significantly increased 5.19 \u00b1 0.67% from baseline in the teriparatide-alone group. In the combination group, lumbar spine (6.19 \u00b1 0.65%), femoral neck (2.23 \u00b1 0.64%), and total hip (2.31 \u00b1 0.56%) BMD significantly increased from baseline to study endpoint, and the increase in total hip BMD was significantly greater than in the teriparatide-alone group (p = 0.04). In the teriparatide-alone group, mean serum calcium levels increased from baseline to endpoint (0.30 \u00b1 0.06 mg\/dl, p &amp;lt; 0.001), whereas mean serum phosphate remained unchanged. In the combination group, mean serum calcium was unchanged, and mean serum phosphate decreased (\u22120.20 \u00b1 0.06 mg\/dl, p &amp;lt; 0.001) from baseline to endpoint. Changes in serum calcium (p &amp;lt; 0.001) and phosphate (p &amp;lt; 0.004) were significantly different between treatment groups. The safety profile of combination therapy was similar to teriparatide alone.<\/jats:p>\n               <jats:p>Conclusions: Combination therapy increased bone formation to a similar degree as teriparatide alone. However, the increase in bone resorption was significantly less and total hip BMD significantly increased for combination therapy compared with teriparatide alone. Combination treatment with raloxifene may thus enhance the bone forming effects of teriparatide. Further studies over longer treatment duration that include fracture endpoints are necessary to fully ascertain the clinical significance of combination raloxifene plus teriparatide therapy in postmenopausal osteoporosis.<\/jats:p>","DOI":"10.1359\/jbmr.050714","type":"journal-article","created":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T07:27:46Z","timestamp":1146122866000},"page":"1905-1911","source":"Crossref","is-referenced-by-count":186,"title":["Combination Teriparatide and Raloxifene Therapy for Postmenopausal Osteoporosis: Results From a 6-Month Double-Blind Placebo-Controlled Trial"],"prefix":"10.1093","volume":"20","author":[{"given":"Chad","family":"Deal","sequence":"first","affiliation":[{"name":"Cleveland Clinic Foundation, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Omizo","sequence":"additional","affiliation":[{"name":"Oregon Osteoporosis Center, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliott N","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Northern California Institute for Bone Health, Oakland, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik F","family":"Eriksen","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Cantor","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmett V","family":"Glass","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L","family":"Myers","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H","family":"Krege","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024013019260019800_bib1","first-page":"637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial","volume":"282","author":"Ettinger","year":"1999","journal-title":"Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA"},{"key":"2024013019260019800_bib2","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"2024013019260019800_bib3","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"2024013019260019800_bib4","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"2024013019260019800_bib5","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","article-title":"Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis","volume":"350","author":"Lindsay","year":"1997","journal-title":"Lancet"},{"key":"2024013019260019800_bib6","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1359\/jbmr.2001.16.10.1846","article-title":"Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study","volume":"16","author":"Dempster","year":"2001","journal-title":"J Bone Miner Res"},{"key":"2024013019260019800_bib7","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1210\/endo.139.11.6307","article-title":"LY353381 \u00d7 HCl: An improved benzothiophene analog with bone efficacy complementary to parathyroid hormone-(1\u201334)","volume":"139","author":"Sato","year":"1998","journal-title":"Endocrinology"},{"key":"2024013019260019800_bib8","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1359\/jbmr.1999.14.5.675","article-title":"The addition of a raloxifene analog (LY117018) allows for reduced PTH(1\u201334) dosing during reversal of osteopenia in ovariectomized rats","volume":"14","author":"Hodsman","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2024013019260019800_bib9","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1359\/jbmr.2001.16.5.925","article-title":"Parathyroid hormone added to established hormone therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal","volume":"16","author":"Cosman","year":"2001","journal-title":"J Bone Miner Res"},{"key":"2024013019260019800_bib10","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI3914","article-title":"Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial","volume":"102","author":"Lane","year":"1998","journal-title":"J Clin Invest"},{"key":"2024013019260019800_bib11","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med"},{"key":"2024013019260019800_bib12","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N Engl J Med"},{"key":"2024013019260019800_bib13","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s001980050236","article-title":"Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group","volume":"10","author":"Meunier","year":"1999","journal-title":"Osteoporos Int"},{"key":"2024013019260019800_bib14","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1210\/jc.2003-1703","article-title":"Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy","volume":"90","author":"Dobnig","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019260019800_bib15","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1359\/jbmr.2003.18.11.1932","article-title":"Recombinant human parathyroid hormone (1\u201334) [teriparatide] improves both cortical and cancellous bone structure","volume":"18","author":"Jiang","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024013019260019800_bib16","first-page":"A469","article-title":"Raloxifene and estrogen preserve PTH-induced bone mass in ovariectomized rats","volume":"10","author":"Bryant","year":"1996","journal-title":"FASEB J"},{"key":"2024013019260019800_bib17","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMe038143","article-title":"Parathyroid hormone plus alendronate\u2014a combination that does not add up","volume":"349","author":"Khosla","year":"2003","journal-title":"N Engl J Med"},{"key":"2024013019260019800_bib18","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s001980070111","article-title":"Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis","volume":"11","author":"Lane","year":"2000","journal-title":"Osteoporos Int"},{"key":"2024013019260019800_bib19","first-page":"620","article-title":"A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis","volume":"82","author":"Hodsman","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019260019800_bib20","first-page":"788","article-title":"Parathyroid responsivity in postmenopausal women with osteoporosis during treatment with parathyroid hormone","volume":"83","author":"Cosman","year":"1998","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2FJBMR.050714","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/20\/11\/1905\/56474737\/5650201102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/20\/11\/1905\/56474737\/5650201102.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:09:57Z","timestamp":1710342597000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/20\/11\/1905-1911\/7592785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,1]]},"references-count":20,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2005,11,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.050714","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2005,11,1]]},"published":{"date-parts":[[2005,11,1]]}}}